Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy

Frontiers in Oncology

Volumn 2 MAY, Issue , 2012, Pages

  Slovin, Susan R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Prostate cancer; Prostate specific antigen; Prostate specific membrane antigen; Vaccines

Indexed keywords

ABIRATERONE ACETATE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANTHRACYCLINE; BEVACIZUMAB; CABAZITAXEL; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DEXAMETHASONE; DNA VACCINE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; ITK 1 PEPTIDE VACCINE; METRONIDAZOLE; NAVELBINE; PACLITAXEL; PEPTIDE VACCINE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELLULAR IMMUNITY; COLON CANCER; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; METRONOMIC DRUG ADMINISTRATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

EID: 84866762187     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00043     Document Type: Review

References (50)

1. Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M., Panicali, D., Beetham, P., Tsang, K. Y., Grosenbach, D. W., Feldman, J., Steinberg, S. M., Jones, E., Chen, C., Marte, J., Schlom, J., and Dahut, W. (2006). A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 12, 1260-1269.
2. Beer, T. M., Slovin, S. F., Higano, C. S., Tejwani, S., Dorff, T. B., Stankevich, E., Lowy, I., and Prostate Cancer Clinical Trials Consortium. (2008). Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol. 26, abstr. 5004.
3. Chakraborty, M., Schlom, J., and Hodge, J. W. (2007). The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol. Immunother. 56, 1471-1484.
4. Chen, C. A., Ho, C. M., Chang, M. C., Sun, W. Z., Chen, Y. L., Chiang, Y. C., Syu, M. H., Hsieh, C. Y., and Cheng, W. F. (2010). Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol. Ther. 18, 1233-1243.
5. Diener, K. R., Woods, A. E., Manavis, J., Brown, M. P., and Hayball, J. D. (2009). Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression. Lab. Invest. 89, 142-151.
6. Disis, M. L. (2011). Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol. Immunother. 60, 433-442.
7. Drake, C. G. (2010). Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10, 580-593.
8. Emmenegger, U., Francia, G., Chow, A., Shaked, Y., Kouri, A., Man, S., and Kerbel, R. S. (2011). Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13, 40-48.
9. Gameiro, S. R., Caballero, J. A., Higgins, J. P., Apelian, D., and Hodge, J. W. (2011). Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses Cancer Immunol. Immunother. 60, 1227-1242.
10. Garnett, C. T., Schlom, J., and Hodge, J. W. (2008). Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin. Cancer Res. 14, 3536-3544.
11. Gerritsen, W., van den Eertwegh, A. J., de Gruijl, T., Giaccone, G., Scheper, R. J., Lowy, I., Levy, E., Hege, K., and Sacks, N. (2008). Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J. Clin. Oncol. 26, abstr. 5146.
12. Grinshtein, N., Ventresca, M., Margl, R., Bernard, D., Yang, T. C., Millar, J. B., Hummel, J., Beermann, F., Wan, Y., and Bramson, J. L. (2009). High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome. Cancer Gene Ther. 16, 338-350.
13. Grivennikov, S. I., Greten, F. R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell 140, 883-899.
14. Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., and Vogelzang, N. J. (2003). Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J. Clin. Oncol. 21, 1232-1237.
15. Higano, D., Saad, F., Somer, B., Curti, B., Petrylak, D., Drake, C. G., Schnell, F., Redfern, C. H., Schrijvers, D., and Sacks, N. (2009). "A phase III trial of GVAX immunotherapy for porstate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC)," in 2009 Genitourinary Cancers Symposium, Abstract LBA150, Orlando, FL.
16. Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., Korman, A., Lautz, D., Russell, S., Jaklitsch, M. T., Ramaiya, N., Chen, T. C., Neuberg, D., Allison, J. P., Mihm, M. C., and Dranoff, G. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U.S.A. 105, 3005-3010.
17. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., and Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
18. Hoos, A., Eggermont, A. M., Janetzki, S., Hodi, F. S., Ibrahim, R., Anderson, A., Humphrey, R., Blumenstein, B., Old, L., and Wolchok, J. (2010). Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 102, 1388-1397.
19. Hoos, A., Parmiani, G., Hege, K., Sznol, M., Loibner, H., Eggermont, A., Urba, W., Blumenstein, B., Sacks, N., Keilholz, U., Nichol, G., and Cancer Vaccine Clinical Trial Working Group. (2007). A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30, 1-15.
20. Javeed, A., Ashraf, M., Riaz, A., Ghafoor, A., Afzal, S., and Mukhtar, M. M. (2009). Paclitaxel and immune system. Eur. J. Pharm. Sci. 38, 283-290.
21. Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W., Schellhammer, P. F., and IMPACT Study Investigators. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422.
22. Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., and Djeu, J. Y. (2010). A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16, 4583-4594.
23. Li, N., Qin, H., Li, X., Zhou, C., Wang, D., Ma, W., Lin, C., Zhang, Y., Wang, S., and Zhang, S. (2007). Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model. Immunol. Lett. 113, 90-98.
24. Ma, Y., Conforti, R., Aymeric, L., Locher, C., Kepp, O., Kroemer, G. C. J., DeMarzo, A. M., Meeker, A. K., Isaacs, W. B., Drake, C. G., and Zitvogel, L. (2011). How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev. 30, 71-82.
25. Madan, R. A., Mohebtash, M., Arlen, P. M., Rauckhorst, M., Ferrara, T. A., Steinberg, S. M., Dahut, W. L., Schlom, J., and Gulley, J. L. (2010a). Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 28, abstr. 2550.
26. Madan, R. A., Gulley, J. L., Fojo, T., and Dahut, W. L. (2010b). Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 15, 969-975.
27. McDonnell, A. M., Nowak, A. K., and Lake, R. A. (2011). Contribution of the immune system to the chemotherapeutic response. Semin. Immunopathol. 33, 353-367.
28. Mlecnik, B., Bindea, G., Pages, F., and Galon, J. (2011). Tumor immunosurveillance in human cancers. Cancer Metastasis Rev. 30, 5-12.
29. Mohebtash, M., Madan, R. A., Arlen, P. M., Rauckhorst, M., Tsang, K. Y., Cereda, V., Vergati, M., Poole, D. J., Dahut, W. L., Schlom, J., Gulley, J. L., and National Cancer Institute Bethesda, MD (2009). Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 27, abstr. 5144.
30. Noguchi, M., Itoh, K., Suekane, S., Morinaga, A., Sukehiro, A., Suetsugu, N., Katagiri, K., Yamada, A., and Noda, S. (2004). Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 60, 32-45.
31. Noguchi, M., Uemura, H., Naito, S., Akaza, H., Yamada, A., and Itoh, K. (2011). A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 71, 470-479.
32. Pagès, F., Galon, J., and Fridman, W. H. (2008). The essential role of the in situ immune reaction in human colorectal cancer. J. Leukoc. Biol. 84, 981-987.
33. Petrylak, D. (2011). "Defining the optimal role of immunotherapy and chemotherapy," in Chemotherapy Foundation Symposium XXIV2006. Available at: http://www.mssmtv.org/player/player.php?id=111006ada_petrylak. [accessed August 24].
34. Petrylak, D. P., Schellhammer, P. F., Small, E., and Frohlich, M. W. (2007). "Androgen independent prostate cancer (AIPC) patients who receive sipuleucel-T followed by docetaxel have prolonged survival," in American Urology Association Meeting Abstracts, Orlando, FL, 605.
35. Poschke, I., Mougiakakos, D., and Kiessling, R. (2011). Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol. Immunother. 60, 1161-1171.
36. Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H. I., Antonia, S., Altiok, S., Celis, E., and Gabrilovich, D. I. (2010). Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 120, 1111-1124.
37. Rini, B. I., Weinber, V., Fong, L., Conry, S., Hershberg, R. M., and Small, E. J. (2006). Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107, 68-74.
38. Saha, A., and Chatterjee, S. K. (2010). Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand. J. Immunol. 71, 70-82.
39. Sarnaik, A. A., Yu, B., Yu, D., Morelli, D., Hall, M., Bogle, D., Yan, L., Targan, S., Solomon, J., Nichol, G., Yellin, M., and Weber, J. S. (2011). Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin. Cancer Res. 17, 896-906.
40. Sfanos, K. S., Bruno, T. C., Maris, C. H., Xu, L., Thoburn, C. J., DeMarzo, A. M., Meeker, A. K., Isaacs, W. B., and Drake, C. G. (2008). Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res. 14, 3254-3261.
41. Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., and Zitvogel, L. (2011). Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol. 33, 369-383.
42. Slovin, S. F. (2008). Tribulations or triumphs in prostate cancer immunotherpy: on the road to victory? Expert Rev. Anticancer Ther. 8, 465-474.
43. Small, E., Demkow, T., Gerritsen, W. R., Rolland, F., Hoskin, P., Smith, D. C., Parker, C., Chondros, D., Ma, J., and Hege, K. (2009). "A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC)," in 2009 Genitourinary Cancers Symposium, Orlando, Abstract LBA150.
44. Vesely, M. D., Kershaw, M. H., Schreiber, R. D., and Smyth, M. J. (2011). Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271.
45. Vicari, A. P., Luu, R., Zhang, N., Patel, S., Makinen, S. R., Hanson, D. C., Weeratna, R. D., and Krieg, A. M. (2009). Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol. Immunother. 58, 615-628.
46. Wada, S., Yoshimura, K., Hipkiss, E. L., Harris, T. J., Yen, H. R., Goldberg, M. V., Grosso, J. F., Getnet, D., Demarzo, A. M., Netto, G. J., Anders, R., Pardoll, D. M., and Drake, C. G. (2009). Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 69, 4309-4318.
47. Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebb, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., Humphrey, R., and Hodi, F. S. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420.
48. Wu, Y., and Zhou, B. P. (2009). Inflammation: a driving force speeds cancer metastasis. Cell Cycle 8, 3267-3273.
49. Yuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H. F., Ritter, E., Ku, G. Y., Jungbluth, A. A., Segal, N. H., Rasalan, T. S., Manukian, G., Xu, Y., Roman, R. A., Terzulli, S. L., Heywood, M., Pogoriler, E., Ritter, G., Old, L. J., Allison, J. P., and Wolchok, J. D. (2008). CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. U.S.A. 105, 20410-20415.
50. Zitvogel, L., Apetoh, L., Ghiringhelli, F., Andre, F., Tesniere, A., and Kroemer, G. (2008). The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest. 118, 1991-2001.